Inquiry Basket
Loading ......
Filter By Product Search for
ABHD5
ABHD5 Full Name
abhydrolase domain containing 5
ABHD5 Introduction
Abhydrolase domain-containing 5 (ABHD5), widely recognized in the scientific community as Comparative Gene Identification-58 (CGI-58), is a pivotal regulator of intracellular lipid metabolism. Although it belongs to the ancient alpha/beta hydrolase fold family, ABHD5 is fundamentally unique because it completely lacks intrinsic hydrolase enzymatic activity due to the absence of a catalytic serine residue in its active site. Instead of functioning as an enzyme itself, ABHD5 operates primarily as a highly specialized, dynamic co-activator protein that dictates the mobilization of stored energetic lipids.
The most critical physiological role of ABHD5 is the potent activation of adipose triglyceride lipase (ATGL), the rate-limiting enzyme responsible for the catabolism of cellular triglycerides. Under basal, non-stimulated conditions, ABHD5 is firmly sequestered on the surface of lipid droplets through direct binding to perilipin-1 (in adipocytes) or perilipin-2 and perilipin-5 (in non-adipose tissues). Upon hormonal stimulation—such as β-adrenergic signaling—Protein Kinase A (PKA) phosphorylates perilipin, causing a rapid conformational change that liberates ABHD5. The released ABHD5 then actively recruits and fully activates ATGL, initiating the massive hydrolysis of triglycerides into diacylglycerols and free fatty acids to meet systemic energy demands. Additionally, emerging evidence indicates that ABHD5 also possesses lysophosphatidic acid (LPA) acyltransferase activity, contributing to the biosynthesis of phosphatidic acid, an essential lipid second messenger and membrane building block.
Figure 1. Schematic representation of basal and stimulated lipolysis in adipose tissue. (Source: Schratter M, et al. 2022)
Clinically, the profound metabolic influence of ABHD5 intimately links its structural or functional dysregulation to severe human pathologies. Loss-of-function mutations in the ABHD5 gene are the direct molecular cause of Chanarin-Dorfman Syndrome (CDS), a rare autosomal recessive lipid storage disorder also known as neutral lipid storage disease with ichthyosis (NLSDI). Patients with CDS experience a massive, systemic accumulation of triglycerides in multiple tissues, manifesting clinically as severe congenital ichthyosis, hepatomegaly, and myopathy. Beyond rare genetic disorders, the suppression of ABHD5 is heavily implicated in metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and aggressive malignancies. In oncology, ABHD5 acts as a robust tumor suppressor. Its epigenetic silencing in colorectal, prostate, and breast cancers drives metabolic reprogramming toward the Warburg effect and promotes the epithelial-mesenchymal transition (EMT), severely exacerbating tumor invasion and metastasis.
Alternate Names for ABHD5
ABHD5; abhydrolase domain containing 5; 1-acylglycerol-3-phosphate O-acyltransferase ABHD5; CGI 58; NCIE2; lipid droplet-binding protein CGI-58; abhydrolase domain-containing protein 5; CDS; CGI58; IECN2; MGC8731;
Loading ......
